Headlines after the bell: T, AMGN, VMW» Read More
But use of Merck& Co's widely prescribed Zetia, which is not a statin, and Vytorin, a related drug, will likely not be badly hurt anytime soon, analysts said, because doctors will need time to understand and accept the new guidelines. The Merck drugs have combined annual sales of more than $4 billion, or 10 percent of overall company revenue.
Pfizer Inc, Amgen Inc and a partnership of Regeneron Inc and French drugmaker Sanofi SA are racing to develop the new family of medicines called PCSK9 inhibitors. "I read the new guidelines as a negative for any drugs that aren't statins, including PCSK9 inhibitors," said Jon LeCroy, an analyst with MKM Partners.
LONDON, Nov 11- Cardiologists and shareholders in GlaxoSmithKline are about to learn if a big gamble on a new kind of heart medicine has paid off, with modest expectations creating a potentially big share price boost if the news is good.
*Grifols shares up 2.3 percent, Novartis adds 0.5 percent. ZURICH/ MADRID, Nov 11- Switzerland's Novartis has agreed to sell its blood transfusion testing unit to Spain's Grifols for $1.68 billion, in an increasingly buoyant market for healthcare deals.
ZURICH/ MADRID, Nov 11- Switzerland's Novartis has agreed to sell its blood transfusion diagnostics unit to Spain's Grifols for $1.68 billion, in an increasingly buoyant market for pharmaceutical mergers and acquisitions.
Nov 5- Keryx Biopharmaceuticals Inc's kidney drug proved effective in treating chronic kidney disease patients not on dialysis, sending the company's shares to a seven-year high on hopes the drug could achieve blockbuster status. "This is great news that opens up the pre-dialysis market for the company," Maxim Group analyst Jason Kolbert told Reuters.
The "Fast Money" traders share their final trades of the day.
Some of the names on the move ahead of the open.
Stocks recovered from session lows to close higher Tuesday, with the S&P 500 hitting a new high above 1,750, after the tepid September jobs report gave further evidence to investors that the Federal Reserve will continue to support the economy at the current pace.
Check out which companies are making headlines after the bell Tuesday:
U.S. stock index futures tread water on Tuesday, ahead of the publication of the government's delayed non-farm payrolls data for September.
Corporate America's third quarter report card is not great, but it's good enough to keep stocks moving higher.
It was a "Who's Who" of guests on "Squawk Box"—everybody from Buffett to Bowles, Tepper to Cooperman, and McCain to Corker. "Talking Squawk," the official show blog, covers them all.
As resources move to other areas, cardiologists fear the battle against heart disease could stall after advances marked by critical drugs to lower cholesterol and blood pressure.
We could be witnessing the beginning of a merger wave in biotech, Jim Cramer said Tuesday.
Stocks reversed their earlier gains in the last hour of trading Monday, with the Dow slipping below the psychologically-important 15,000 level.
U.S. stock index futures traded flat Monday after briefly spiking lower following the weaker-than-expected durable goods orders.
Chris Raymond, Robert W. Baird analyst, discusses details of the fifth-biggest biotech deal in history, and the expanding field of biotech cancer drugs.
Amgen has struck a $10 billion-plus deal to buy Onyx Pharmaceuticals, ending a two-month-long auction for the cancer drugmaker.
Amgen is close to buying Onyx for $125 per share, or more than $10 billion, in a deal that is expected to be announced as soon as Monday, two people familiar with the matter said on Saturday.